Chadi Nabhan, Chief Medical Officer and Head of Strategy at Ryght, shared on LinkedIn:
“A new chapter in multiple myeloma may have just begun.
With the FDA approval of iberdomide—the first CELMoD approved in myeloma—we may be witnessing the arrival of an important new therapeutic class.
What makes CELMoDs different? Where will iberdomide fit? And could this class eventually change how we treat myeloma across multiple lines of therapy?
On today’s Healthcare Unfiltered, I discuss this with two of the world’s leading myeloma experts. Sagar Lonial, MD and Vincent Rajkumar, joined the show in a timely conversation to talk about this class of drugs, data on CELMoDs, how they fit in treating myeloma, and next steps.
Streaming everywhere. Please subscribe, share, and join the conversation.”
Other posts featuring Chadi Nabhan on OncoDaily.